Plain-English translation of NCT06342037 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
The TONIC-3 trial is testing three different combinations of immunotherapy medications — including and — to find better ways to treat advanced triple negative breast cancer. Current immunotherapy treatments work for only some patients and don't always keep working long-term, so this study is exploring whether combining multiple medications might be more effective.
Many patients with this type of breast cancer don't respond well to standard immunotherapy, or their cancers come back after initial improvement. This trial aims to find new treatment combinations that work better for more patients.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to receive one of three medication combinations given as injections every three weeks. You'll need to have biopsies and blood tests to help researchers understand how your cancer responds. Throughout the study, you'll have regular clinic visits to check on your health and monitor how the treatment is working.
AI-generated summary from trial data · Aug 14, 2026 · Not medical advice
Netherlands
Phase
Testing effectiveness
Sponsor
The Netherlands Cancer Institute
Collaborators
Hoffmann-La Roche
Enrollment target
~60 participants
Started
June 2024
Primary completion
April 2026
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years and older
Last updated on clinicaltrials.gov in September 2024.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Marleen Kok, MD
Antoni van Leeuwenhoek
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.